VIGIL NEUROSCIENCE INC (VIGL)
US92673K1088 - Common Stock
Why Is Tonix Pharmaceuticals (TNXP) Stock Down 33% Today?
Tonix Pharmaceuticals stock is falling on Thursday after the company announced a proposed public offering for shares of TNXP.
Which stocks are moving before the opening bell on Thursday?
Which stocks are moving before the opening bell on Thursday?
Why Is Branchout Food (BOF) Stock Down 39% Today?
Branchout Food stock is down on Thursday after the company priced an offering of 1.75 million shares of BOF at 80 cents each.
Why Is Vigil Neuroscience (VIGL) Stock Up 32% Today?
Vigil Neuroscience stock is up with heavy trading of VIGL shares this morning on news of a $40 million investment from Sanofi.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are worth checking out on Thursday as we dig into all of the biggest news moving shares this morning!
Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi
Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi
- Sanofi to invest $40 million at an as-converted price of $7.44 per share of common stock- - Sanofi to receive an exclusive right of first negotiation...
3 Penny Stocks With the Power to 10X Your $1k Investment: June Edition
Penny stocks are risky because of their insane volatility — but these have a chance to 10x your investments.
3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition
Don’t miss out on these three penny stocks, which have amazing potential to take off following upcoming business developments this year.
Vigil Neuroscience to Present in Upcoming June Investor Conferences
Vigil Neuroscience to Present in Upcoming June Investor Conferences
WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to...
Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference
Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference
WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will participate in a fireside chat at the Citizens JMP Life Sciences Conference on Tuesday, May 14th at 11:30 a.m. E.T.
VIGL Stock Earnings: Vigil Neuroscience Beats EPS for Q1 2024
VIGL stock results show that Vigil Neuroscience beat analyst estimates for earnings per share the first quarter of 2024.
VIGL Stock Earnings: Vigil Neuroscience Beats EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vigil Neuroscience (NASDAQ:VIGL) just reported results for the first quarter of...
Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update
Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update
– Enrollment completed for Phase 2 trial evaluating iluzanebart in ALSP; Next data readout planned for Q3 2024 – – Phase 1 healthy volunteer trial...
Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting
Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting
- Findings from ILLUMINATE Natural History Study show that MRI and fluid biomarkers are emerging as key measures of ALSP pathophysiology - - Positive...
VIGL Stock Earnings: Vigil Neuroscience Misses EPS for Q4 2023
VIGL stock results show that Vigil Neuroscience missed analyst estimates for earnings per share the fourth quarter of 2023.
VIGL Stock Earnings: Vigil Neuroscience Misses EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vigil Neuroscience (NASDAQ:VIGL) just reported results for the fourth quarter o...
Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
– Reported positive interim data from Phase 2 IGNITE proof-of-concept clinical trial evaluating iluzanebart (VGL101) for treatment of ALSP –
Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer
Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer
WATERTOWN, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to...
Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting
Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting
WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to...
Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days
Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days
WATERTOWN, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to...
Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024
Presentation highlights potential for VG-3927 to treat neurodegenerative diseases associated with microglial dysfunction, like AD, due to its differentiated neuroprotective profile and ability to favorably tune microglia activation
Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024
Presentation highlights potential for VG-3927 to treat neurodegenerative diseases associated with microglial dysfunction, like AD, due to its...
Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024
Poster highlights clinical overlap of ALSP and multiple sclerosis (MS) and details patients’ barriers to genetic testing WATERTOWN, Mass., Feb. 29,...
Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conference
Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conference
WATERTOWN, Mass. , Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to...
Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones
Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones
- On track to report interim Phase 1 data for VG-3927 in healthy volunteers in mid-2024 and Phase 2 results from IGNITE clinical trial evaluating...